Evidence map›Paper›PMID 42168488›Full record

ReviewDiscover oncology2026

The impact of m6A modified cargo conveyed by exosomes on the tumor microenvironment.

Wang Yi, Qingfeng Shi, Jiahui Wu, Boxuan Zhou, Yingliang Li

Abstract readReview
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wang YiDepartment of Breast Disease Center, The First Affiliated Hospital of Nanchang University, The First Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang, 330006, P.R. China.
Qingfeng ShiDepartment of Breast Disease Center, The First Affiliated Hospital of Nanchang University, The First Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang, 330006, P.R. China.
Jiahui WuDepartment of Plastic Surgery, The Second Clinical Medical College of Nanchang University, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang, 330006, P.R. China.
Boxuan ZhouDepartment of Breast Disease Center, The First Affiliated Hospital of Nanchang University, The First Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang, 330006, P.R. China. zhoubx@ncu.edu.cn.
Yingliang LiDepartment of Breast Disease Center, The First Affiliated Hospital of Nanchang University, The First Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang, 330006, P.R. China. liyingliang@163.com.

Funding

Jiangxi Province' Ganpo Talent Program' Innovation Leadership Talent gpyc20240199Key Project of Jiangxi Provincial Department of Education GJJ2400104Technology Plan Project of Jiangxi Provincial Administration of Traditional Chinese Medicine 2024A0090, 2024A0196The Full time Talent Introduction and Research Start up Fund of the First Affiliated Hospital of Nanchang University RSC-0020the Natural Science Foundation of Jiangxi Province 20242BAB20404, 20252BAC240624The Youth Talent Research Training Foundation of the First Affiliated Hospital of Nanchang University YFYPY2023103
6 · The paper itself

Abstract

The dynamic evolution of tumor microenvironment (TME) is the core of cancer progression. N6-methyladenosine (m6A) modification and exosome transport are key layers of post-transcriptional gene regulation and intercellular communication, respectively. However, the intersection of these two systems, namely the transportation of m6A modified bioactive cargoes through exosomes and reshaping of TME, still lacks systematic sorting. This review aims to fill this gap. Through systematic searches of PubMed, Scopus, and Web of Science, we identified 21 original preclinical studies focused on this area over the past five years. By analyzing these literature, a conceptual framework for the "m6A-exosome axis" was established for the first time, and how it mediates TME and its effects were elucidated. We found that bioactive molecules modified with m6A can be transported to TME through exosomes. During this process, these molecules can reshape existing stromal cells and immune cells, activate tumor associated cytokines, and regulate the malignant phenotype of tumor cells. This TME remodeling further affects pathological processes such as tumor angiogenesis, epithelial mesenchymal transition (EMT), immune escape, metastasis, and drug resistance. These findings indicate that the key components of this axis not only serve as potential biomarker candidates, but also represent a promising preclinical therapeutic target. Targeting this axis provides an innovative combination strategy framework for overcoming tumor growth and metastasis.

Indexed as

BiomarkerCancerExosomem6AProteinRNATargeted therapyTumor microenvironment

Identifiers

PMID42168488
PMCPMC13490356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.